Serum levels of IL-32 in patients with type 2 diabetes mellitus and its relationship with TNF-α and IL-6

Fadaei, Reza; Bagheri, Nader; Heidarian, Esfandiar; Nouri, Ali; Hesari, Zahra; Ahmadi, Alireza; Ahmadi, Reza

doi:10.1016/j.cyto.2019.154832

Cited by 44 publications

(31 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It implies that other factors arising from obesity or comorbidities might have stronger influence on the atherosclerotic process and the subsequent vascular events. There are inflammatory mediators associated with obesity and T2D, such as inteleukin-6 (IL-6), IL-32, tumor necrosis factor -α (TNF-α) [18], that have a direct effect on vascular wall and plaque formation [23], but they are not within the scope of this work. To note that the correlations of the obesity measures with the levels of the CV biomarkers (ADMA, ET-1 and NT-proBNP) are practically not significant.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Body composition indices and cardiovascular risk in type 2 diabetes. CV biomarkers are not related to body composition

et al. 2020

View full text Add to dashboard Cite

AbstractBackgroundThis study aims to explore the correlations of body mass index (BMI), waist circumference (WC), waist-to-height ratio (WHtR), waist-to-hip ratio (WHR) and body composition with levels of asymmetric dimethylarginine (ADMA), endothelin 1(ET-1), N-terminal brain natriuretic pro-peptide (NT-proBNP) and calculated cardiovascular risks.Methods102 women and 67 men with type 2 diabetes participated. Serum levels of NT-proBNP were measured by electro-hemi-luminescence while ELISA were used for ADMA and ET-1. Cardiovascular risks were calculated using the Framingham Risk Score (FRS), the UKPDS 2.0 and the ADVANCE risk engines. Statistical analysis was performed on an IBM SPSS 19.0.ResultsThe BMI outperformed all other indices of obesity (WC, WHtR, WHR), as well as body composition parameters (body fat%, fat mass, fat free mass and total body water) in relation to the estimated risks for coronary heart disease and stroke, based on different calculators. The correlations of the obesity indices with the serum cardiovascular biomarkers were not significant except for BMI and fat mass versus ET-1, and for fat free mass and total body water versus ADMA.ConclusionsThe WC, WHR, WHtR, BF%, FM and FFM apparently do not add significant information related to the levels of cardiovascular biomarkers or the calculated CV-risks.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It affects the endothelium through hemodynamic changes, leading to its dysfunction and increased levels of inflammatory markers [15]. T2D and obesity are also linked to higher inflammatory state [18], and in combination with hypertension they might potentiate each other, leading to a greater CV-risk [16].…”

Section: Introductionmentioning

confidence: 99%

Body composition indices and cardiovascular risk in type 2 diabetes. CV biomarkers are not related to body composition

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Nine different IL-32 isoforms have been identified [26], and among them, IL-32α, IL-32β and IL-32γ are the most representative forms [26]. In this study, mirroring what was already done in others' papers measuring the levels of IL-32 as biomarker of diseases, we used ELISA kit to be able to recognise the three main isoforms (α, β and γ), as reported by others [34,50,51]. Considering that the main goal of our work was to assess the possible use of IL-32 as a new and relevant biomarker to discriminate those SSc patients at higher risk of PAH, we did not analysed the specific role of any isoform.…”

Section: Discussionmentioning

confidence: 78%

Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension

et al. 2020

View full text Add to dashboard Cite

Background: Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), associated with a progressive elevation in pulmonary vascular resistance and subsequent right heart failure and death. Due to unspecific symptoms, the diagnosis of PAH is often delayed. On this basis, it is of great value to improve current diagnostic methods and develop new strategies for evaluating patients with suspected PAH. Interleukin-32 (IL-32) is a proinflammatory cytokine expressed in damaged vascular cells, and the present study aimed to assess if this cytokine could be a new biomarker of PAH during SSc. Methods: The IL-32 expression was evaluated in the sera and skin samples of 18 SSc-PAH patients, 21 SSc patients without PAH, 15 patients with idiopathic PAH (iPAH) and 14 healthy controls (HCs), by enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC). Receiver-operating characteristic (ROC) curves were performed to evaluate the cutoff of IL-32 in identifying patients with PAH. Furthermore, in SSc patients, correlation analyses were performed between IL-32 sera levels and mean pulmonary artery pressure (mPAP) evaluated by right heart catheterization (RHC) and systolic pulmonary artery pressure (sPAP), obtained by echocardiography. Additionally, the number of skin IL-32+ cells was correlated with modified Rodnan skin score (mRSS). Results: In SSc-PAH patients, IL-32 sera levels were significantly higher when compared with SSc patients without PAH and patients affected by iPAH. The analysis of ROC curve showed that IL-32 sera levels above 11.12 pg/ml were able to predict patients with PAH (sensitivity = 90%, specificity = 100%). Furthermore, the IL-32 sera levels of patients with SSc correlated with both mPAP and sPAP. In the skin derived from SSc-PAH patients, the number of IL-32+ cells was significantly increased when compared with the skin derived from SSc patients without PAH, correlating with the mRSS. Conclusion: Our study suggested that sera determination of IL-32 may be a promising approach to evaluate the presence of PAH in SSc patients and together with longitudinal future studies could help to increase the understanding how these biomarkers mirror the vascular changes and the inflammatory process during SSc.

show abstract

“…High level IL-6, TNF-α and other inflammatory cytokines are expressed in the serum of individuals with diabetes [7]. Moreover, animal models suggested that diabetes significantly promoted the production of TLR4-induced IL-6 [8].…”

Section: How Does Diabetes Accentuate Covid-19 Morbidity?mentioning

confidence: 99%

Saudi Scientific Diabetes Society Position Statement: Management of Diabetes Mellitus in the Pandemic of COVID-19

Alshaikh¹,

Alsifri²,

Alhozali³

et al. 2020

IJCM

View full text Add to dashboard Cite

About 10% coronavirus (COVID-19) infected patients are with diabetes comorbidity. Also, diabetes promotes severe progression in COVID-19 patients. Diabetes comorbidity is associated with significant mortality in those people with COVID-19. In this position statement, the management of diabetes in cases of COVID-19, has been presented. The impact of diabetes on the morbidity and mortality of COVID-19, as well as both the target glucose level and the method of blood glucose control have been presented in details.

show abstract

Serum levels of IL-32 in patients with type 2 diabetes mellitus and its relationship with TNF-α and IL-6

Cited by 44 publications

References 28 publications

Body composition indices and cardiovascular risk in type 2 diabetes. CV biomarkers are not related to body composition

Body composition indices and cardiovascular risk in type 2 diabetes. CV biomarkers are not related to body composition

Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension

Saudi Scientific Diabetes Society Position Statement: Management of Diabetes Mellitus in the Pandemic of COVID-19

Contact Info

Product

Resources

About